ストックスクリーナーアプリを入手
6.13
3.31%
-0.21
アフターアワーズ：
6.23
0.10
+1.63%
Corbus Pharmaceuticals Holdings Inc (CRBP) 最新ニュース
Corbus starts TEMPO-1. Corbus Pharmaceuticals stock has 8 Buy ratings - AD HOC NEWS
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Four parties report the same Corbus (CRBP) stake, held directly by one fund. - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer - Yahoo Finance
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Why Is Corbus Pharmaceuticals (NASDAQ:CRBP) Moving Into Focus? - kalkinemedia.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Cannabis Stocks Stock Everyone's About to Talk About? - kalkinemedia.com
(CRBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
symbol__ Stock Quote Price and Forecast - CNN
What Did CANYON Study Data Show for Corbus Pharmaceuticals (NASDAQ:CRBP)? - Kalkine Media
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals stock holds at USD 1.56 - AD HOC NEWS
Corbus Pharmaceuticals (CRBP) Edges Higher: Shares Gain 1.18% to Close at $7.74Earnings Beat Stocks - dars.gov.et
CRBP - Finviz
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data? - Yahoo Finance
H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Corbus Pharmaceuticals Holdings Inc. Stock Rallies 4.9%, Outperforms Peers - webull.com
Corbus Pharmaceuticals Insider Ben Yong Offloads 2,000 Shares at $7.84 Each (NASDAQ: CRBP) - Kalkine Media
Corbus Pharmaceuticals Holdings Inc. Stock Slides 14.4%, Underperforms Peers - webull.com
H.C. Wainwright reiterates Corbus stock rating on phase 1b data By Investing.com - Investing.com UK
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study - Yahoo Finance
Corbus reports phase 1b obesity drug trial results By Investing.com - Investing.com South Africa
CRBP: CRB-913 achieved 5% weight loss in 12 weeks with favorable safety, supporting further clinical development - TradingView
CRBP: CRB-913 achieved 5% weight loss in 12 weeks with mild side effects, supporting further development - TradingView
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $33 - Moomoo
Why is Corbus Pharmaceuticals stock surging today? By Investing.com - Investing.com Canada
Form 8K Corbus Pharmaceuticals Holding For: 14 September By Investing.com - Investing.com India
Corbus Pharmaceuticals stock rises on obesity drug trial data By Investing.com - Investing.com Australia
CRBP: CRB-701 and CRB-913 show promising efficacy and safety, advancing to pivotal studies - TradingView
Corbus Pharmaceuticals stock rises on obesity drug trial data - Investing.com
Corbus Pharmaceuticals Reports Positive Topline Data From CANYON-1 Study Of Daily Oral CRB-913 For Obesity Treatment - marketscreener.com
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity - The Manila Times
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity - Yahoo! Finance Canada
We Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Needs To Drive Business Growth Carefully - Moomoo
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings stock holds steady ahead of next results - AD HOC NEWS
How Corbus Pharmaceuticals Holdings Inc. (CRBP) Affects Rotational Strategy Timing - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals Holding (CRBP) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Corbus (CRBP) Outlook: Finishes 4.62% Higher at $10.86 for the Current Session - vinanet.vn
Corbus Pharmaceuticals Holdings, Inc. Revenue Breakdown – NASDAQ:CRBP - TradingView
CRBP’s CRB-701 Phase 3 Trial Sets the Stage for a Key Oncology Catalyst - The Globe and Mail
0.05%
0.82%
大文字化:
|
ボリューム (24 時間):